Name: 5th Annual MarketsandMarkets Biomarker and Companion Diagnostics Conference
Start: 2020-02-06
End: 2020-02-07
Location: Sheraton San Diego Hotel & Marina, 1380 Harbor Island Dr, CA 92101, United States

30+

Speaker

10+

Networking Hours

4+

Sessions

200+

Attendees

The 5th Annual Biomarker and Companion Diagnostics Conference scheduled to be held on 6th - 7th February 2020 in San Diego, CA would address the gaps between early-stage biomarker development and the commercialization stage of biomarkers. This conference would also highlight case studies on leveraging emerging technologies in Digital Biomarkers, Precision Medicine and Big Data. Regarding the commercialization of biomarkers, leading industry and academic experts would share their case studies focusing on advancements in the companion diagnostics areas. The keynote presentations would also help the attendees understand the issues related to clinical translation of biomarkers.

30+ experts from academia and industry will be presenting their current work in Biomarkers, Latest updates on regulatory guidelines and approvals, Cancer biomarker validation for clinical application, Biomarkers and Personalized Medicine, Impact of Big data in translational biomarker research and Future of Companion Diagnostics

Opportunity to develop long-lasting business relationships and networking opportunities with researchers, scientists, clinicians, academicians and professionals from Pharmaceutical companies, Bio-pharma companies, Universities, and Research institutes.

Over 20 presentations, round-tables, and panel discussions focused on the key opportunities and challenges in biomarker research, from precision medicine and companion diagnostics through to digital biomarkers and clinical trials.

Researchers, Scientists & Clinicians who are active in:

Biomarker discovery/development
Translational research
Clinical Biomarker
Biomarkers in IO and Neurological disorders
Imaging Biomarkers
Companion Diagnostics
Biomarker Imaging
Proteomics Biomarkers
Experimental Medicine
Data Science
Biomarkers in Clinical Discovery
Immuno-oncology/Neuroscience Drug Discovery
Diagnostic Biomarkers development

Biomarker Drug Discovery and Assay Development
Proteomics and Genomics based Biomarkers
Digital Biomarkers, Precision Medicine and Big Data
Predictive Biomarkers in targeted Cancer Therapy
CDx development and Commercialization
Clinical Applications of Biomarkers in Immuno-Oncology
Neurology and Inflammatory Diseases

Biomarkers In Clinical & Translational Development: Drug Discovery And Assay Development
Innovations In Biomarker Research: Digital Biomarkers, Precision Medicine And Big Data
From Biomarkers To Cdx: Strategies To Accelerate Cdx Development And Commercialization
Clinical Applications Of Biomarkers In Immuno-oncology, Neurology And Inflammatory Diseases

CONFERENCE AGENDA

Registration	08:15 - 08:45
Welcome note from MarketsandMarkets Shekhar Gupta , Geography Head-US, MarketsandMarkets	08:45 - 09:05
Opening Remarks from the Chairman Naveen Babbar , Executive Director, Precision Medicine Leader, Novartis	09:05 - 09:10
Keynote Presentation Lokesh Agrawal , Program Director, Biorepositories and Biospecimen Research Branch (BBRB), , NIH	09:10 - 09:40
BIOMARKERS IN CLINICAL & TRANSLATIONAL DEVELOPMENT: DRUG DISCOVERY AND ASSAY DEVELOPMENT
New Directions in Biomarkers for CAR-T Therapies in Multiple Myeloma Majid Ghoddusi , Senior Director, Clinical Biomarkers, Poseida Therapeutics	09:40 - 10:10
Non-invasive Precision Genomics in Dermatology Burkhard Jansen , Chief Medical Officer , Dermtech	10:10 - 10:25
Morning Refreshments and Poster Presentation \| One-to-One Networking Meetings	10:25 - 11:10
Enhanced Biomarker Discovery and Validation Using TMT® Proteomics Jessica McDonough, Co-Founder, Attivare Therapeutics	11:10 - 11:40
Interpreting the complexity of cancer with blood-based biomarkers for both tumor and immune profiling Linda Traylor , Vice President, Clinical Development & Medical Affairs, Biodesix	11:40 - 12:10
Blood-based Traumatic Brain Injury Biomarkers: past, present and future Kevin Wang, Director, Program for Neuroproteomics and Biomarkers Research, University of Florida	12:10 - 12:40
Streamlined CDx® Program - Accelerating Drug Approvals Worldwide Jeffrey Miller, CSO & CEO, Invivoscribe	12:40 - 13:10
Lunch and Poster Presentation \| One-to-One Networking Meetings	13:10 - 14:10
INNOVATIONS IN BIOMARKER RESEARCH: DIGITAL BIOMARKERS, PRECISION MEDICINE AND BIG DATA
Precision Medicine and Immuno-Oncology Drug Development	14:10 - 14:40
AI For Digital Biomarker Discovery Christelle Fasano, Senior Director, Business Development, Pharma & Biotech, Imagia	14:40 - 14:55
Business of Fit-for-Purpose: From Sample Management to Validation to Final Sample Analysis Data Amber Donahue, Biomarker Clinical Assay Lead, Pfizer	14:55 - 15:25
Empowering Patients & Physicians: A Novel Clinical Trial for Molecular Disease Characterization Kristin Blouch, Director, Head of RWE & Molecular Disease Characterization, Experimental Medicine Unit, GSK	15:25 - 15:55
Afternoon Refreshments and Poster Presentation \| One-to-One Networking Meetings	15:55 - 16:40
Using complex genetic/biomarker information to optimize trial design and developing efficient statistical algorithms to identify patient subgroups with better/worse responses/survival profile to a particular treatment Vicky Wu, Co-Investigator, Fred Hutch	16:40 - 17:10
Developing global and gene specific methylation tools for drug development	17:10 - 17:25
Panel Discussion: Biomarker strategies and partnering with medical device companies Karina Besprosvan , Datastoryteller Insight & Innovation Exponential C, Sony Pictures Entertainment	17:25 - 17:55
Closing Remarks from the Chairman	17:55 - 18:00
Drinks Reception & Networking	18:00 - 19:00

Registration	08:15 - 09:00
Welcome note from MarketsandMarkets	09:00 - 09:05
Opening Remarks from the Chairman Majid Ghoddusi , Senior Director, Clinical Biomarkers, Poseida Therapeutics	09:05 - 09:10
Keynote Presentation: Mechanisms of Toxicity, Resistance and Response to anti-CD19 CAR T cell Therapy in LCL John Rossi, Vice President, Head, Translational Medicine, , Syncopation Lifesciences	09:10 - 09:40
FROM BIOMARKERS TO CDX: STRATEGIES TO ACCELERATE CDX DEVELOPMENT AND COMMERCIALIZATION
An Integrated Oncology Platform for Biomarker Discovery and Companion Diagnostics Development Nicole Niu , Executive Director , Crown Bioscience	09:40 - 10:10
Tempus \| Making the Promise of Precision Medicine a Reality Michael Yasiejko , Chief Commercial Officer, Tempus	10:10 - 10:25
Morning Refreshments and Poster Presentation \| One-to-One Networking Meetings	10:25 - 11:10
Integration of biomarker validation in clinical development: a statistical perspective Elisabeth Coart, Director, Consulting Services, IDDI	11:10 - 11:40
Eutropics’ Praedicare DxTM platform providing predictive functional biomarkers for AML Michael Cardone, CEO , Eutropics Pharmaceuticals Inc.	11:40 - 11:55
Accurate Plasma Biomarker Detection for Clinical Trials & Clinical Practice: Why Sensitivity Matters Dan Edelstein , Vice President, Commercial Operations, Sysmex Inostics	11:55 - 12:10
Companion Diagnostic Development in Gene Expression for Challenging Sample Types BJ Kerns, Vice President, Scientific Collaborations , HTG Molecular Diagnostics	12:10 - 12:40
Companion Diagnostic Development: How to Ensure Program Success Kristina McGuire, Executive Director and Head of CDx & Lab Operations, Precision Medicine, Regeneron Pharmaceuticals	12:40 - 13:10
Lunch and Poster Presentation \| One-to-One Networking Meetings	13:10 - 14:10
CLINICAL APPLICATIONS OF BIOMARKERS IN IMMUNO-ONCOLOGY, NEUROLOGY AND INFLAMMATORY DISEASES
Increasing Complexity in Tissue Based Diagnostics Scott Boyer, Business Development Manager, Leica Biosystems	14:10 - 14:25
A universal early cancer screen using a blood-based 400K frameshift peptide array Yisrael Katz, Senior Medical Director , Viracta Therapeutics, Inc.	14:25 - 14:55
Immuno-Oncology Biomarkers Identified by Novel Digital Pathology Approaches Jennifer Bordeaux , Principal Investigator, Navigate BioPharma	14:55 - 15:25
Targeting extrachromosomal DNA (ecDNA), a new approach to treating cancers with high copy number gene amplification Jason Christiansen, Chief Technology Officer, Boundless Bio	15:25 - 15:55